RedHill Biopharma Receives Approval for COVID-19 Phase 2/3 Study with Opaganib in the UK The Phase 2/3 multi-center, randomized, double-blind, parallel-arm, placebo-controlled study with opaganib aims to enroll 270 severe COVID-19 patients in up to 40 clinical sites across the UK, Italy,...

Additional Update on COVID-19 Compassionate Use with Opaganib in Israel Provided by RedHill Biopharma All five patients have shown an improved CRP, with four of the five patients also demonstrating measurable clinical improvement, including required supplemental oxygenation and higher lymphocyte...